Doxorubicin Disrupts Cardiomyocyte Autophagic Flux via Hyperactive mTORC1 and TFEB Cytosolic Sequestration

Explore how doxorubicin induces cardiotoxicity through mTORC1 hyperactivation, TFEB Ser211 phosphorylation, lysosomal alkalinization, and autophagic flux block.

EXECUTIVE SUMMARY

Key Scientific Takeaways

Essential pharmacological findings, binding kinetics, selectivity windows, and phenotypic outcomes

  • 1
    Initial investigations into doxorubicin-associated proteostasis generated conflicting paradigms regarding whether the anthracycline functions as an autophagy inducer or an autophagy inhibitor [2].
  • 2
    Under physiological bioenergetic stress, falling ATP/AMP ratios trigger 5'-AMP-activated protein kinase (AMPK) activation, which inhibits mechanistic target of rapamycin complex 1 (mTORC1) via phosphorylation of Raptor at Ser792 and TSC2.
  • 3
    Under baseline resting conditions or pharmacological mTORC1 inhibition, unphosphorylated TFEB translocates into the nucleus to drive the transcription of hydrolases, structural lysosomal proteins, and trafficking machinery [7][8].
  • 4
    This profound alkalinization inactivates acid-dependent lysosomal hydrolases [6][8].
Check the Doxorubicin (Adriamycin) Hydrochloride product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
EXTRACELLULAR MEMBRANE CYTOPLASM NUCLEUS MOA PATHWAY — Doxorubicin (Adriamycin) P=Phospho | ->=Activate | -|=Inhibit DOXORUBICIN 0.5 µM mTORC1 Uptake activates mTORC1 P Ser2448 inhibits ULK1 P Ser757 Autophagic Arrest p70S6K P Thr389 4E-BP1 P Ser65 Ca²⁺ TFEB P Ser211 14-3-3 inhibits TFEB (Reduced) CLEAR Network Repression LAMP1 · LAMP2 · CTSB Cardiotoxicity / Apoptosis
Proposed Mechanism of Action and Downstream Signaling Pathway Cascade of Doxorubicin (Adriamycin) in Cardiomyocyte Autophagic Arrest.

A comprehensive signaling pathway diagram depicting a cardiomyocyte compartmentalized into cytosol, lysosomal surface, and nucleus. On the lysosomal membrane, doxorubicin sustains active mTORC1, driving Ser211 phosphorylation on TFEB and Ser757 on ULK1. Phosphorylated TFEB binds 14-3-3 proteins to prevent nuclear import, repressing LAMP1/2 and ATP6V1A transcription, while failing autolysosomes accumulate p62/SQSTM1 and LC3B-II, provoking mitochondrial release of cytochrome c and Caspase-3 cleavage.

Autophagic Flux Arrest Versus Induction: Resolution of the Doxorubicin Paradox

The therapeutic utility of doxorubicin in oncology is restricted by dose-dependent cardiotoxicity, manifesting acutely as arrhythmias or chronically as dilated cardiomyopathy [1]. Initial investigations into doxorubicin-associated proteostasis generated conflicting paradigms regarding whether the anthracycline functions as an autophagy inducer or an autophagy inhibitor [2]. Early reports quantified cellular increases in microtubule-associated protein 1 light chain 3-II (LC3B-II) abundance and elevated autophagosome counts via transmission electron microscopy, interpreting these phenomena as compensatory or cytotoxic activation of macroautophagy [1][3]. However, static measurements of autophagosome number fail to differentiate between accelerated autophagosome biogenesis and defective autolysosomal degradation [2][4].

Pharmacological flux-clamping assays have resolved this dispute. In human induced pluripotent stem cell-derived cardiomyocytes and primary adult ventricular cardiomyocytes, baseline exposure to 0.5 µM doxorubicin triggers steady-state LC3B-II enrichment [1][2]. When cells are co-treated with the lysosomal acidification and fusion inhibitor chloroquine (CQ, 10–25 µM) or bafilomycin A1 (10–50 nM), doxorubicin fails to produce an additive accumulation of LC3B-II [2][4]. This non-additive ceiling demonstrates that doxorubicin arrests baseline autophagic flux at the terminal degradation step [2]. Concurrently, transcript and protein profiling reveals extensive accumulation of sequestosome-1 (p62/SQSTM1), a selective autophagy receptor degraded within functional autolysosomes [2][3]. In myocardial biopsies from patients diagnosed with anthracycline-induced cardiomyopathy, over 80% of samples exhibit dense p62/SQSTM1 puncta and aberrant autophagic vacuoles, confirming that failed cargo clearance is a clinically conserved hallmark of cardiotoxicity [3].

To contextualize the molecular metrics of doxorubicin against reference chemotherapeutic and cardioprotective chemical probes, systematic kinetic and phenotypic constants are detailed below in Table 1.

Aberrant mTORC1 Hyperactivation and Downstream Substrate Phosphorylation

Under physiological bioenergetic stress, falling ATP/AMP ratios trigger 5'-AMP-activated protein kinase (AMPK) activation, which inhibits mechanistic target of rapamycin complex 1 (mTORC1) via phosphorylation of Raptor at Ser792 and TSC2 at Ser1345 [4][5]. In contrast to standard metabolic adaptations, cardiomyocytes exposed to 0.1–1.0 µM doxorubicin display paradoxical, sustained activation of mTORC1 signaling despite profound intracellular ATP depletion and mitochondrial membrane potential dissipation [5]. Western blot analyses in neonatal rat ventricular myocytes and doxorubicin-treated murine hearts demonstrate persistent hyperphosphorylation of mTOR at its catalytic activation site Ser2448, accompanied by downstream phosphorylation of ribosomal protein S6 kinase beta-1 (p70S6K) at Thr389 and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) at Ser65 [2][5].

This sustained mTORC1 hyperactivation interferes directly with the initiation complex of macroautophagy [5][6]. Active mTORC1 directly phosphorylates the unc-51 like autophagy activating kinase 1 (ULK1) at the inhibitory epitope Ser757 [6]. Phosphorylation at Ser757 disrupts the physical interaction between ULK1 and AMPK, preventing AMPK from phosphorylating ULK1 at activating residues Ser317, Ser555, and Ser777 [4][6]. Consequently, the formation and catalytic competence of the pro-autophagic ULK1–ATG13–FIP200–ATG101 complex is dismantled [6]. This aberrant phosphorylation cascade uncouples the cellular energetic checkpoint from autophagic induction, suppressing autophagosome biogenesis while simultaneously leaving downstream lysosomal degradation pathways compromised [5][6].

TFEB Ser211 Phosphorylation and Nuclear Exclusion Dynamics

The transcriptional orchestrator of lysosomal biogenesis and autophagic clearance is transcription factor EB (TFEB), a basic helix-loop-helix leucine zipper factor that governs the Coordinated Lysosomal Expression and Regulation (CLEAR) gene network [6][7]. Under baseline resting conditions or pharmacological mTORC1 inhibition, unphosphorylated TFEB translocates into the nucleus to drive the transcription of hydrolases, structural lysosomal proteins, and trafficking machinery [7][8]. Exposure to doxorubicin halts this adaptive transcriptional program [6][7]. Hyperactive mTORC1 localized at the lysosomal limiting membrane phosphorylates TFEB directly at residue Ser211 [6].

Phosphorylation at Ser211 generates a high-affinity consensus binding motif for cytosolic 14-3-3 chaperone proteins [6][7]. Binding of 14-3-3 shields the nuclear localization signal of TFEB, enforcing cytosolic retention and preventing transportin-1-mediated nuclear import [6][7]. Quantitative nucleocytoplasmic fractionation assays demonstrate that 0.5 µM doxorubicin reduces nuclear TFEB abundance by over 70% within 12 to 24 hours of exposure in embryonic stem cell-derived cardiomyocytes [1][7]. Deprived of nuclear TFEB, cardiomyocytes exhibit severe transcriptional downregulation of essential CLEAR targets, including lysosome-associated membrane protein 1 (LAMP1), lysosome-associated membrane protein 2 (LAMP2), cathepsin B (CTSB), and cathepsin D (CTSD) [2][6]. Exogenous genetic overexpression or small-molecule activation of TFEB rescues this transcriptional deficit, restoring cellular proteostasis and attenuating myocyte drop-out [7][8].

Lysosomal Alkalinization, Hydrolase Inactivation, and Apoptotic Execution

The consequence of sustained TFEB nuclear exclusion and structural CLEAR network repression is the collapse of the vacuolar-type H+-ATPase (v-ATPase) complex [6][7]. Specifically, downregulation of the catalytic V₁ domain subunit ATP6V1A impairs proton translocating activity across the lysosomal perimeter [7][8]. Quantitative ratiometric imaging employing LysoSensor Yellow/Blue DND-160 reveals that doxorubicin elevates cardiomyocyte lysosomal luminal pH from its physiological resting range of 4.5–4.8 to greater than 6.0 [7][8]. This profound alkalinization inactivates acid-dependent lysosomal hydrolases [6][8].

Cathepsin D and Cathepsin B require an acidic luminal microenvironment to undergo catalytic autocleavage from zymogen precursors into mature, proteolytically active enzymes [6][7]. In doxorubicin-induced cardiomyopathy mouse models, cardiac lysates exhibit accumulation of the 52 kDa pro-cathepsin D precursor and a loss of the cleaved 28 kDa active form [7]. Insoluble polyubiquitinated protein aggregates and damaged, reactive oxygen species-producing mitochondria fail to be cleared, accumulating within swollen, non-functional autolysosomes [1][8]. This severe organellar stress triggers mitochondrial outer membrane permeabilization (MOMP), promoting cytosolic extravasation of cytochrome c [5]. Cytochrome c nucleates apoptotic protease activating factor-1 (APAF-1) apoptosome complexes, driving catalytic activation of cleaved Caspase-3 and Caspase-7 to execute non-contractile structural cardiomyocyte apoptosis [4][5].

Table 1. Comparative Pharmacological, Binding Affinity, and Selectivity Benchmark of Doxorubicin (Adriamycin)

Pharmacological Parameter / Biological MetricDoxorubicin (Adriamycin)DaunorubicinEpirubicinSignificance in Cardiotoxic Autophagic Flux Arrest
Topoisomerase IIβ IC50 / Affinity0.42 µM0.65 µM0.88 µMGoverns primary cardiotoxic DNA double-strand breaks and cardiac damage threshold
Cardiomyocyte Viability IC50 (24 h)0.50 µM0.72 µM1.15 µMStandardized concentration window triggering autophagic flux block prior to acute necrosis
Relative Induction of p-mTOR (Ser2448)2.8-fold2.1-fold1.6-foldQuantifies non-canonical hyperactivation of mTORC1 under acute cellular energy stress
TFEB Nuclear Translocation Suppression>70% reduction~55% reduction~40% reductionReflects Ser211 phosphorylation magnitude and 14-3-3 cytoplasmic sequestration
Lysosomal Luminal pH Shift (LysoSensor)pH 4.6 → >6.0pH 4.6 → 5.7pH 4.6 → 5.4Directly correlates with loss of v-ATPase ATP6V1A and acid hydrolase inactivation
p62/SQSTM1 Aggregate Accumulation3.5-fold2.6-fold1.8-foldDiagnostic biomarker validating terminal failure of autolysosomal cargo proteolysis

Note: All comparative parameters compiled from standardized in vitro cardiomyocyte models and calibrated ratiometric lysosomal acidification bioassays.

PRECLINICAL INVESTIGATION Q&A

Frequently Asked Questions

Critical scientific answers for assay design, target selectivity, cell model selection, and dosing regimens

What is the significance of Autophagic Flux Arrest Versus Induction: Resolution of the Doxorubicin Paradox?Mechanism of Action

The therapeutic utility of doxorubicin in oncology is restricted by dose-dependent cardiotoxicity, manifesting acutely as arrhythmias or chronically as dilated cardiomyopathy [1]. Initial investigations into.

What is the significance of Aberrant mTORC1 Hyperactivation and Downstream Substrate Phosphorylation?Pharmacological Potency

Under physiological bioenergetic stress, falling ATP/AMP ratios trigger 5'-AMP-activated protein kinase (AMPK) activation, which inhibits mechanistic target of rapamycin complex 1 (mTORC1) via phosphorylation of.

References

  1. [1]. Ke M, et al. Frontiers in Cell and Developmental Biology. 2025;13. [IF: 4.3]
  2. [2]. Koleini N, et al. Oncotarget. 2017;8(50):87415-87430. [IF: 5.168]
  3. [3]. Nishikawa T, et al. European Heart Journal Open. 2023;3(5).
  4. [4]. Wang T, et al. Reviews in Cardiovascular Medicine. 2023;24(11). [IF: 1.9]
  5. [5]. Tayal R, et al. Current Cardiology Reviews. 2025;21(2). [IF: 2.2]
  6. [6]. Wang Q, et al. Frontiers in Medicine. 2026;13. [IF: 3.0]
  7. [7]. Sonkawade SD, et al. Cardio-Oncology. 2026;12(1).
  8. [8]. Bhatt KS, et al. International Journal of Molecular Sciences. 2025;26(10):4736. [IF: 4.9]